National Pharmaceutical Council, 1717 Pennsylvania Avenue, NW Washington, DC 20006, USA.
Social & Scientific Systems, 8757 Georgia Avenue, Silver Spring, MD 20910, USA.
J Comp Eff Res. 2016 Mar;5(2):207-16. doi: 10.2217/cer-2015-0018. Epub 2016 Feb 4.
Five annual surveys of healthcare decision-makers potentially affected by comparative effectiveness research (CER) indicate sustained recognition of its importance and potential impact. Initial expectations of immediate CER impact have over time turned to stakeholder assessments of little short-term impact. In successive surveys, they project a continuous horizon of 3-5 years for CER to have a moderate or substantial improvement in decision making. The prominence of Patient-Centered Outcomes Research Institute in CER is highlighted by stakeholders, but greater emphasis on translating and disseminating research findings is needed, a role in which Agency for Healthcare Research and Quality is expected to contribute. Stakeholders, including patients, must be engaged throughout to ensure that findings provide the flexibility for decision makers to apply them to their patient populations.
五项年度调查显示，医疗保健决策者可能会受到比较效果研究（CER）的影响，这些决策者持续认识到 CER 的重要性和潜在影响。最初对 CER 即时影响的期望随着时间的推移已转变为利益相关者对短期影响甚微的评估。在连续的调查中，他们预测 CER 将在 3-5 年内对决策产生适度或重大的改善。利益相关者强调了患者为中心的成果研究所在 CER 中的突出地位，但需要更加重视研究结果的转化和传播，这是医疗保健研究和质量机构（AHRQ）预计将发挥的作用。利益相关者，包括患者，必须全程参与，以确保研究结果为决策者提供灵活性，以便将其应用于患者群体。
